Wednesday, December 11th, 2024: Day TwoWednesday, 11 December 2024 - ET (Eastern Time, GMT-05:00)

Hear from top executives from healthcare stakeholders on on how their organizations are taking action on initiatives to:

• Improve patient affordability
• Promote health equity
• Shift towards value
• Protect and support innovation

As the roles between trade and channel, patient services and market access becomes more and more intertwined, hear directly from Ultragenyx on their strategies for ensuring cross functional collaboration and success for their programs.

• Learn how to leverage provider and patient journey insights to improve dialogue and understanding between health systems and pharmaceutical companies, ensuring alignment and collaborative success in new medication launches
• Discover innovative methods to identify and dismantle traditional barriers that impede effective partnerships, fostering a culture of openness and cooperation that accelerates the adoption of new medical innovations
• Gain insights into creative strategies and unconventional approaches that can redefine how health systems and pharma collaborate, leading to more effective and efficient launch processes and better patient outcomes

• Explore how to target underexplored markets, utilizing payer dynamics to open new doors in health system partnerships
• Gain insights from the strategies and challenges of working in the “Grey Space”, where innovation and collaboration converge, enabling us to navigate uncertainty and uncover shared solutions
• Gain real-world examples on how to transform partnerships and redefine your organization’s market position

• As cell and gene therapies revolutionize patient care, understand the challenges for stakeholders in implementing breakthrough treatments
• Dive into the intricacies of channel strategies specific to cell and gene therapy procurement models, particularly within hospitals and health systems
• Gain insights into the evolving landscape of these advanced therapies, addressing the procurement hurdles, cost considerations, and supply chain implications